NICE(UK) is unable to make a recommendation about the use in the NHS of brensocatib for treating non-cystic fibrosis bronchiectasis in people 12 years and over. This is because… read more.
Eli Lilly and Company announced that the FDA approved Mounjaro (tirzepatide), a dual GIP and GLP-1 hormone receptor agonist, to lower the risk of major adverse cardiovascular (CV)… read more.
Pfizer Inc. and BioNTech SE announced that the FDA has approved the supplemental Biologics License Application (sBLA) for the companies’ 2026-2027 COVID-19 vaccine formula targeting the XFG variant… read more.
A supplemental New Drug Application for approval of Zegfrovy (sunvozertinib) in the 1st-line setting has been accepted by the FDA, supported by positive results from the global WU-KONG28… read more.
The National Institute for Health and Care Excellence (NICE) has issued nine Technology Appraisal decisions in August 2026, comprising five positive first recommendations, one updated positive recommendation, and… read more.
GE HealthCare recently achieved CE Mark for Photonova Spectra, an advanced photon-counting computed tomography (PCCT) system with the company’s proprietary Deep Silicon detector technology. The regulatory milestone expands… read more.
Quest Diagnostics announced two new developments for its Quest AD-Detect portfolio of blood-based biomarker tests for Alzheimer’s disease, with the goal of broadening access to quality blood tests… read more.
BioMarin Pharmaceutical Inc. announced that it has entered into binding terms with Ascendis Pharma A/S, resolving the patent and ancillary disputes pending globally, including before the U.S. International… read more.
Immedica announces that Japan’s Ministry of Health, Labor and Welfare (MHLW) has granted Orphan Drug Designation (ODD) to pegzilarginase for the treatment of arginase 1 deficiency (ARG1-D), a… read more.
Egetis Therapeutics AB announced that its partner Fujimoto Pharmaceutical Corporation, which has an exclusive license agreement to develop and commercialize Emcitate (tiratricol) for the treatment of MCT8 deficiency… read more.
Gilead Sciences, Inc. announced that the EC has granted marketing authorization for Trodelvy (sacituzumab govitecan-hziy) in combination with Keytruda (pembrolizumab) for the treatment of adult patients with unresectable,… read more.
NICE (UK) is unable to make a recommendation about the use in the NHS of lisocabtagene maraleucel for treating relapsed or refractory follicular lymphoma in adults after 2… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
